RxDoctor Payments DataLook up a doctor →

Michael Carlson, MD

Endocrinology, Diabetes & Metabolism · Nashville, TNNPI 1386639219

Payments from drug & device makers

$381,306in general payments, 2019–2025

Across 1,788 payments — averaging $213.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$192K
  • Amgen$58K
  • Lilly USA, LLC$36K
  • Boehringer Ingelheim$30K
  • AstraZeneca$28K
  • AbbVie$19K
  • plus $16K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk375$191,927
Amgen(2 entities)211$58,475
Lilly USA, LLC208$36,314
Boehringer Ingelheim108$30,418
AstraZeneca(2 entities)117$28,446
AbbVie61$19,447
Corcept Therapeutics53$3,272
Abbott112$2,183
Sanofi-aventis U.S. LLC63$1,119
BETA Bionics, Inc.27$942
Xeris Pharmaceuticals, Inc.42$877
Mannkind Corporation58$673
Medtronic(2 entities)27$646
Insulet Corporation32$560
IBSA Pharma Inc.30$529
Cequr Corporation3$459
Ascensia Diabetes Care US Inc.8$421
Dexcom, Inc.21$361
Tandem Diabetes Care, Inc.16$355
Pfizer19$323
Merck26$287
Zealand Pharma US, Inc.15$285
Ascendis Pharma Endocrinology Inc8$271
Ultragenyx Pharmaceutical Inc.10$260
Radius Health, Inc.14$220
Shire North American Group Inc8$166
Bayer9$164
Neurocrine Biosciences, Inc.5$151
Antares Pharma, Inc.7$120
Kyowa Kirin, Inc.6$116
Novartis6$97
Esperion Therapeutics, Inc.5$95
Sequel Med Tech, LLC4$93
Chiesi USA, Inc.4$92
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC6$89
Recordati_rare_diseases_inc.5$88
Takeda Pharmaceuticals U.S.A., Inc.5$72
Valeritas, Inc.4$68
Nestle Healthcare Nutrition Inc.3$66
Amneal Pharmaceuticals LLC4$63
Verity Pharmaceuticals Inc.3$53
Amphastar Pharmaceuticals, Inc.3$48
Clarus Therapeutics Inc.3$48
Madrigal Pharmaceuticals2$47
Lifescan, Inc.3$47
Nevro Corp.2$46
Rhythm Pharmaceuticals, Inc.3$45
Amarin Pharma, Inc.3$43
Amryt Pharma Holdings Ltd2$41
Companion Medical, Inc.3$39
Regeneron Healthcare Solutions, Inc.3$37
Ipsen Biopharmaceuticals, Inc2$34
Senseonics, Incorporated2$26
Axsome Therapeutics, Inc.1$26
Astellas Pharma US Inc1$19
Halozyme Inc1$16
Sanofi US Services Inc.1$15
Genentech USA, Inc.1$15
Bigfoot Biomedical Inc1$14
Johnson & Johnson1$14

How this compares

$381,306 in reported general payments places this provider in the 85th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.

See all endocrinology, diabetes & metabolism providers in Tennessee →

Medicare billing

Part B allowed, 2024
$238,858
Medicare patients
318
Services billed
6,642

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Nashville

See the full list for Tennessee →

Where these figures come from

Is this you, or does something look wrong? →